Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogenic bone marrow-derived mesenchymal stem cells (Pere Gines)
- Development stage
- Unknown
- Lead developer
- Hospital Clínic de Barcelona
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogenic bone marrow-derived mesenchymal stem cells (MSCs) are an investigational cell therapy being evaluated for the treatment of acute-on-chronic liver failure (ACLF) in patients with cirrhosis. Developed by a team led by Dr. Pere Ginès at the Hospital Clínic de Barcelona, this therapy involves the intravenous infusion of MSCs obtained from healthy bone marrow donors. The primary therapeutic hypothesis is that these cells can mitigate the intense systemic inflammatory response characteristic of ACLF through immunomodulatory paracrine signaling, thereby reducing organ failure and improving survival. The 'Liveradvance' trial represents one of the key clinical efforts to validate the safety and efficacy of this approach in a randomized, placebo-controlled setting.
- Other names
- Allogenic mesenchymal stem cellsAllogenic MSCsBone marrow-derived mesenchymal stem cells
Beyond the preview
Go deeper on allogenic bone marrow-derived mesenchymal stem cells (Pere Gines).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogenic bone marrow-derived mesenchymal stem cells (Pere Gines).